Effects of the Use of "de Novo" Everolimus in Renal Tranplant Population

Exclusion Criteria

• •The subject, in the opinion of the investigator, is not able to complete the study protocol;
• •Recipient of live-donor kidney graft;
• •Multiple organ transplant recipient;
• •Evidence of large systemic or localized infection;
• •Evidence of infiltration, cavitation or consolidation on chest X-rays obtained during the evaluation in the screening / baseline visit;
• •Use of any drug under investigation or treatment until up to 4 weeks before transplantation;
• •Known or suspected hypersensitivity to tacrolimus, everolimus or mycophenolate sodium;
• •Immunosuppressive therapies in addition to those described for this study;
• •Hypersensitized patients (PRA \> 30%);
• •Patients with HIV+ or Hepatitis B or C virus infection.
• •Patients for whom T0 and T15 biopsies were not taken.